Request initial doses ERVEBO®
ERVEBO® is approved by FDA for prevention of Ebola virus disease (EVD) in people 12 months of age and older. Pre-exposure vaccination with ERVEBO is recommended for adults aged ≥18 years in the U.S. population who are at highest risk for potential occupational exposure to Ebola virus (species Zaire ebolavirus, or EBOV) because they are:
- Ebola virus disease (EVD) responders: Individuals responding to an outbreak due to Ebola virus (species Zaire ebolavirus).
- Laboratorians and support staff: Individuals working at facilities (e.g., biosafety level 4 or Laboratory Response Network facilities) in the United States that handle specimens that contain or might contain replication-competent Ebola virus (species Zaire ebolavirus).
- Healthcare personnel (HCP): HCP at federally designated Ebola or state-designated Special Pathogens Treatment Centers involved in the care and transport of patients infected or suspected to be infected with Ebola virus (species Zaire ebolavirus).
ERVEBO is not planned for commercial marketing but is maintained in the Strategic National Stockpile (SNS) with vaccine access within the United States facilitated by the U.S. government. The Centers for Disease Control and Prevention will provide ERVEBO when requested by licensed healthcare providers from institutions or sites with individuals who meet the eligibility criteria included in the Use of Ebola Vaccine: Expansion of Recommendations of the Advisory Committee on Immunization Practices to Include Two Additional Populations—United States, 2021 | MMWR (cdc.gov).
Licensed healthcare providers interested in initial doses of ERVEBO for patients that meet the eligibility criteria should send an email to firstname.lastname@example.org with subject line: Request for ERVEBO. The CDC Ebola Vaccine Program will respond with the required instructions and forms for eligible requests.
The duration of protection conferred by an initial dose of ERVEBO is unknown. Clinicians may be able to request booster doses for eligible individuals who were previously vaccinated (e.g., ≥ 6 months since prior vaccination) under an expanded access IND protocol.